Background & aim: Dyslipidemia, characterized by hyper-cholesterolemia and hypertriglyceridemia, is a central component of metabolic dysfunction-associated steatohepatitis (MASH) pathogenesis. While being highly instrumental in drug development, preclinical models of MASH often fail to recapitulate a human-like lipoprotein profile. To enhance…
Background & aim: Histopathological fibrosis staging is a key endpoint in preclinical drug development for MASH. However, the MASH CRN (Kleiner) system assigns one global stage per biopsy, potentially obscuring subtle treatment-related collagen remodelling and tissue heterogeneity. We developed an…
Background & aim: Fibroblast growth factor 21 (FGF21) plays a key role in hepatic lipid metabolism and holds great promise as therapeutic target for metabolic dysfunctionassociated steatohepatitis (MASH). Efruxifermin (EFX) is a long acting FGF21 analogue currently in phase 3…
Background & aim: Fibroblast growth factor 21 (FGF21) plays a key role in hepatic lipid metabolism and holds great promise as therapeutic target for metabolic dysfunction-associated steatohepatitis (MASH). Efruxifermin (EFX) is a long-acting FGF21 analogue currently in phase 3 clinical…
Background & aim: Resmetirom (RES, THR-βR agonist) has recently been FDA-approved for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). Other drug concepts are in late-stage clinical development for MASH, including semaglutide (SEMA, GLP1R agonist), tirzepatide (TZP, GLP1R-GIPR co-agonist) and efruxifermin…
